- Home
- SLRC vs TNGX Comparison
SLRC vs TNGX Comparison
Compare SLRC & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRC
- TNGX
- Stock Information
- Founded
- SLRC 2007
- TNGX 2014
- Country
- SLRC United States
- TNGX United States
- Employees
- SLRC N/A
- TNGX N/A
- Industry
- SLRC Finance/Investors Services
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SLRC Finance
- TNGX Health Care
- Exchange
- SLRC Nasdaq
- TNGX Nasdaq
- Market Cap
- SLRC 889.2M
- TNGX 723.2M
- IPO Year
- SLRC 2010
- TNGX N/A
- Fundamental
- Price
- SLRC $16.43
- TNGX $6.90
- Analyst Decision
- SLRC Hold
- TNGX Strong Buy
- Analyst Count
- SLRC 6
- TNGX 6
- Target Price
- SLRC $16.13
- TNGX $10.00
- AVG Volume (30 Days)
- SLRC 149.7K
- TNGX 1.9M
- Earning Date
- SLRC 08-05-2025
- TNGX 08-05-2025
- Dividend Yield
- SLRC 9.98%
- TNGX N/A
- EPS Growth
- SLRC N/A
- TNGX N/A
- EPS
- SLRC 1.63
- TNGX N/A
- Revenue
- SLRC $222,445,000.00
- TNGX $24,296,000.00
- Revenue This Year
- SLRC N/A
- TNGX N/A
- Revenue Next Year
- SLRC $0.22
- TNGX N/A
- P/E Ratio
- SLRC $10.09
- TNGX N/A
- Revenue Growth
- SLRC N/A
- TNGX N/A
- 52 Week Low
- SLRC $13.64
- TNGX $1.03
- 52 Week High
- SLRC $17.94
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- SLRC 52.85
- TNGX 56.63
- Support Level
- SLRC $16.26
- TNGX $6.60
- Resistance Level
- SLRC $16.62
- TNGX $7.42
- Average True Range (ATR)
- SLRC 0.22
- TNGX 0.47
- MACD
- SLRC 0.02
- TNGX -0.04
- Stochastic Oscillator
- SLRC 75.70
- TNGX 57.20
About SLRC SLR Investment Corp.
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. It invests majorly in leveraged middle-market companies in the form of senior secured loans, financing leases and to a lesser extent, unsecured loans and equity securities.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.